MedX Health Corp. Consulting with Medical Advisory Boards Across North America
MedX Health Corp. Consulting with Medical Advisory Boards Across North America
"This technology has the potential to save many lives as an effective triage tool," said Dr. Daniel Siegel, Chair of the U.S.-based Medical Advisory Board. "Scanning more at-risk patients in easy to access locations will provide greater early detection of cancerous and pre-cancerous lesions, providing better patient outcomes while lowering overall healthcare costs. MedX's DermSecure® platform offers a very complete teledermatology solution – with their unique imaging technology, they can provide dermatologists with high resolution images of pigmented lesions for evaluation along with multispectral images that enhance diagnostic accuracy. Until now, most teledermatology offerings could not provide high quality images of potentially deadly melanomas to dermatologists for assessment. This is truly an industry gamechanger." Panels of dermatologists convened to explore clinical applications of SIAscopy® and DermSecure® technology
皮膚科專家小組召開會議，探討該技術在臨牀上的應用。SIA鏡術®和DermSecure® 技術
MISSISSAUGA, Ontario--(BUSINESS WIRE)--$MDX #SkinCancer--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX) recently convened Medical Advisory Boards of leading dermatologists across Canada and the United States to explore clinical application opportunities for its image capture technology, SIAscopy® and patient management system, DermSecure®.
安大略省密西索加--(美國商業新聞網)--$MDX#皮膚癌--MedX Health Corp.(“MedX”或“公司”)(TSXV： MDX)最近召集了加拿大和美國的領先皮膚科醫生組成的醫療顧問委員會，探索其圖像捕獲技術SIAscope的臨牀應用機會®和患者管理系統，DermSecure®.
Summarized findings from both advisory boards will help validate the technological uses and benefits of SIAscopy® in clinical practice, particularly as a triage tool for dermatological assessment of suspicious moles and lesions. The Medical Advisory Boards' recommendations will be compiled and published in the coming months through separate publication pertaining to the Canadian and U.S. markets.
這兩個諮詢委員會的總結結果將有助於驗證SIAscope的技術用途和好處®在臨牀實踐中，特別是作為皮膚科評估可疑痣和皮損的分診工具。醫療諮詢委員會的建議將在未來幾個月通過與加拿大和美國市場有關的單獨出版物進行彙編和公佈。
"This technology has the potential to save many lives as an effective triage tool," said Dr. Daniel Siegel, Chair of the U.S.-based Medical Advisory Board. "Scanning more at-risk patients in easy to access locations will provide greater early detection of cancerous and pre-cancerous lesions, providing better patient outcomes while lowering overall healthcare costs. MedX's DermSecure® platform offers a very complete teledermatology solution – with their unique imaging technology, they can provide dermatologists with high resolution images of pigmented lesions for evaluation along with multispectral images that enhance diagnostic accuracy. Until now, most teledermatology offerings could not provide high quality images of potentially deadly melanomas to dermatologists for assessment. This is truly an industry gamechanger."
美國醫學諮詢委員會主席Daniel Siegel博士説：“作為一種有效的分診工具，這項技術有可能拯救許多人的生命。”在容易接近的地方掃描更多的高危患者將提供更早的癌症和癌前病變檢測，在降低整體醫療成本的同時提供更好的患者結果。MedX的DermSecure®該平臺提供了非常完整的遠程皮膚病解決方案-憑藉其獨特的成像技術，他們可以為皮膚科醫生提供用於評估的色素病變的高分辨率圖像以及可提高診斷準確性的多光譜圖像。到目前為止，大多數遠程皮膚科產品都不能為皮膚科醫生提供高質量的潛在致命黑色素瘤的圖像以供評估。這是一個真正的行業遊戲改變者。“
Dr. Charles Lynde, Chair of the Canadian-based Medical Advisory Board, said, "This technology shows tremendous promise for positively impacting patient care, particularly as a tool for patients and clinicians seeking second opinions. Because of the quality of SIAscopy's® high resolution images, we're also interested in its potential for assessing a wide range of additional skin conditions."
總部設在加拿大的醫學諮詢委員會主席查爾斯·林德博士説：“這項技術在積極影響患者護理方面顯示出巨大的希望，特別是作為患者和臨牀醫生尋求第二意見的工具。這是因為SIAscope的質量。®除了高分辨率圖像，我們還對它評估各種額外皮膚狀況的潛力感興趣。“
A similar Medical Advisory Board consultation process is also underway in the United Kingdom, which will be shortly followed by the formation of a European-based Medical Advisory Board.
英國亦正進行類似的醫務顧問委員會諮詢工作，不久便會成立一個以歐洲為基地的醫務諮詢委員會。
MedX's SIAscopy® is the only technology on the market that captures five high resolution images, including four spectrophotometric images 2mm below the skin's surface, enabling dermatological assessment of suspicious moles and lesions in a pain-free, non-invasive manner. Combined with MedX's DermSecure® Screening Platform – its secure, cloud-based patient management system – these high resolution images are transmitted safely and securely for virtual dermatological assessment by a certified dermatologist within just 72 hours, compared to a wait time of five months to one year for traditional dermatological assessment.
MedX公司的SIA型內窺鏡檢查®該產品是市場上唯一一項能夠捕捉5幅高分辨率圖像的技術，其中包括4幅位於皮膚表面2 mm以下的分光光度計圖像，從而可以無痛、非侵入性地對可疑痣和皮損進行皮膚學評估。與MedX的DermSecure相結合®其安全、基於雲的患者管理系統-篩查平臺-這些高分辨率圖像可在72小時內安全可靠地傳輸，由認證皮膚科醫生進行虛擬皮膚病評估，而傳統皮膚病評估需要5個月至一年的等待時間。
About MedX:
關於MedX：
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485-certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are approved by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com/.
MedX總部位於加拿大安大略省，是一家專注於皮膚健康的領先醫療設備和軟件公司，其SIAscope®論DermSecure®遠程醫療平臺--利用其SIAscope®技術SIA鏡術®也嵌入在其產品SIAMETRICS中®、SIMSYS®和MoleMate®，MedX在其通過國際標準化組織13485認證的工廠生產。SIAMETRICS®、SIMSYS®和MoleMate®包括手持設備，它使用專利技術，利用光及其匯款，以無痛、非侵入性的方式查看可疑痣和病變下長達2毫米的情況，然後通過其軟件創建實時圖像，供醫生和皮膚科醫生在幾秒鐘內評估所有類型的痣或病變。這些產品獲得了加拿大衞生部、美國食品和藥物管理局、治療商品管理局和ConformitéEuropéenne的批准，可在加拿大、美國、澳大利亞、新西蘭、歐盟、巴西和土耳其使用。請訪問https://medxhealth.com/.。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
本新聞稿可能包含前瞻性陳述，這些陳述反映了公司目前對未來事件的預期。前瞻性陳述涉及風險和不確定因素。
Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547
比爾·米圖拉斯(Bill Mitoulas)，投資者關係部
MedX Health Corp.
郵箱：Bill@medxHealth.com
+1-416-479-9547
譯文內容由第三人軟體翻譯。
